Skip to content

Fixed-weight antibody PK and driven-target reference

Three specified constant-weight PK contexts with apparent distribution, a one-way driven target-coordinate observer and explicit drug and target accounting.

Physiologically Based Pharmacokinetic Modeling of Monoclonal Antibodies in Pediatric Populations Using PK-Sim ↗

Frontiers in Pharmacology

Exploration notes · What are you exploring?

Notes stay on this browser.

MODEL IN MOTION 18 sec

How does the pediatric palivizumab preset distribute drug between compartments?

Run settings

Run location

Explore this model

Choose a scenario, adjust inputs, and run the simulation.

Palivizumab fixed 7 kg, 105 mg reference

Authored fixed-weight compartmental reference with supplied coefficients and initialized target coordinates; no growth or full PBPK interpretation.

0–120 day

Scenario details

Palivizumab fixed 7 kg, 105 mg reference

Authored fixed-weight compartmental reference with supplied coefficients and initialized target coordinates; no growth or full PBPK interpretation.

Readouts

Central concentration · ug/mL
Apparent central plasma concentration
Exposure (AUC) · ug/mL*day
AUC ug ml day
Accounted drug · mg
Drug budget equals initial amount plus delivered boluses
Free target concentration · uM
target free uM
Drug–target complex concentration · uM
complex uM

Study purpose

  • How do the model's key biological readouts change under palivizumab fixed 7 kg, 105 mg reference?

Assumptions

  • Interpret patterns within this model and starting configuration; do not treat them as clinical predictions or treatment recommendations.

Inputs changed since the displayed result. Run to update the comparison.

Loading starting example…

Edit inputs

Simulation time
day
day
120 → 168

Time between reported samples.

day

1 change · Variation 1

Continue in the background and keep the result.

Biology

Three specified constant-weight PK contexts with apparent distribution, a one-way driven target-coordinate observer and explicit drug and target accounting.

Three specified constant-weight PK contexts with apparent distribution, a one-way driven target-coordinate observer and explicit drug and target accounting.

Model details

18 parameters · 10 states · 10 equations · 36 derived outputs

Classification & API access
Therapeutic
Palivizumab / Bevacizumab
Modality
Monoclonal antibody
Target
RSV F protein, VEGFA, FcRn
Disease / scope
Pediatric therapeutic-protein dose and exposure scaling
ParameterDefaultUnitDescription
Clearance covariate factorCL_covariate_factor1—Fixed supplied coefficient for the selected context, without an editable, fitting or population domain.
Clearance exponentCL_exponent0.75—Fixed supplied coefficient for the selected context, without an editable, fitting or population domain.
Systemic clearanceCL_mL_day_70kg198mL/dayFixed supplied coefficient for the selected context, without an editable, fitting or population domain.
Q exponentQ_exponent0.75—Fixed supplied coefficient for the selected context, without an editable, fitting or population domain.
Intercompartmental clearanceQ_mL_day_70kg879mL/dayFixed supplied coefficient for the selected context, without an editable, fitting or population domain.
Central distribution volumeVc_L_70kg4.09LFixed supplied coefficient for the selected context, without an editable, fitting or population domain.
Central distribution volume covariate factorVc_covariate_factor1—Fixed supplied coefficient for the selected context, without an editable, fitting or population domain.
Central distribution volume exponentVc_exponent1—Fixed supplied coefficient for the selected context, without an editable, fitting or population domain.
Peripheral distribution volumeVp_L_70kg2.23LFixed supplied coefficient for the selected context, without an editable, fitting or population domain.
Peripheral distribution volume exponentVp_exponent1—Fixed supplied coefficient for the selected context, without an editable, fitting or population domain.
Body weightbody_weight_kg70kgFixed supplied coefficient for the selected context, without an editable, fitting or population domain.
Complex degradationcomplex_degradation_1_day01/dayFixed supplied coefficient for the selected context, without an editable, fitting or population domain.
Drug concentration conversion factordrug_ug_ml_per_uM150(µg/mL)/µMFixed supplied coefficient for the selected context, without an editable, fitting or population domain.
Dissociation rate targetkoff_target_1_day01/dayFixed supplied coefficient for the selected context, without an editable, fitting or population domain.
Association rate target 1 umkon_target_1_uM_day01/µM/dayFixed supplied coefficient for the selected context, without an editable, fitting or population domain.
Reference weightreference_weight_kg70kgFixed supplied coefficient for the selected context, without an editable, fitting or population domain.
Target concentration umtarget_concentration_uM0µMFixed supplied coefficient for the selected context, without an editable, fitting or population domain.
Target synthesistarget_synthesis_1_day01/dayFixed supplied coefficient for the selected context, without an editable, fitting or population domain.

Related models

Bevacizumab and VEGF165 conditional QSS bindingBevacizumab exposure: adult and pediatric reference profilesEculizumab fixed PK and authored response diagnosticsAtezolizumab exposure across pediatric and young-adult cohorts

Feedback: helpdesk@unibiointelligence.com.

Ubi Biologics